Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS)

BMC Cancer

Research Article

Mathieu Laramas¹  Laetitia Stefani²  Françoise Ducimetiere³  Jean-Yves Blay³  Isabelle Ray-Coquard⁴  Sébastien Clippe⁵  Olivier Collard⁶  Nadine Ladarre⁷  Bertrand Tehard⁷  Stephanie Manson⁸  Jean-Philippe Suchaud⁹  Florence Mercier^1,10 

[1] CHU de Grenoble, Avenue Maquis du Grésivaudan, 38700, La Tronche, France;Centre Hospitalier Annecy-Genevois, 1 Avenue de l’Hôpital, 74370, Metz-Tessy, France;Centre Léon-Bérard, University Claude Bernard Lyon I, 28 rue Laennec, 69008, Lyon, France;Centre Léon-Bérard, University Claude Bernard Lyon I, 28 rue Laennec, 69008, Lyon, France;Service D’oncologie Médicale, Centre Léon Bérard, 28, rue Laennec, 69008, Lyon, France;Centre Marie Curie, 137 Avenue de Romans, 26000, Valence, France;Institut de Cancérologie de la Loire Lucien Neuwirth, 108 Bis av. Albert Raimond, 42270, Saint-Priest en Jarez, France;Novartis, 2-4, rue Lionel Terray, Boite postale 308, F-92506, Rueil-Malmaison Cedex, France;Novartis, Park View, Riverside Way, Watchmoor Park, GU15 3YL, Camberley, Surrey, UK;Service de Radiothérapie, Centre Hospitalier de Roanne, 28 Rue de Charlieu, 42300, Roanne, France;Stat Process, 52 Boulevard Sébastopol, 75003, Paris, France;

关键词: Sarcoma;    Treatment;    Survival;    Metastatic;    Chemotherapy;    Database;   

DOI  :  10.1186/s12885-017-3057-3

 received in 2016-08-19, accepted in 2017-01-11,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundThe French EMS study prospectively collected exhaustive data from STS patients diagnosed in the Rhone-Alpes region from 2005 to 07.MethodsThe database included diagnosis/histology, surgery, radiotherapy, systemic treatments and treatment response. Treatment patterns and outcomes of patients with metastatic disease, excluding adipocytic sarcoma and GIST were analyzed.ResultsOf 888 total patients, 145 were included based on having metastatic disease and appropriate subtypes. All patients received treatment with systemic therapy being most common (74%, n = 107), followed by radiotherapy (30%, n = 44) and surgery (23%, n = 33). Doxorubicin, alone or in combination, was the most common first line systemic therapy (65%, n = 46). Drugs without license in sarcoma were used in 38–83% of treatments depending on treatment line. 24% of frontline patients demonstrated an objective response, decreasing to 11% objective responses in second line but no responses were documented beyond second line, with median PFS declining with each additional line. Median PFS also declined in patients receiving surgery compared to those receiving no surgery (8–15 m vs 5 m). Median OS from metastatic diagnosis for patients receiving systemic therapy was double that of patients without systemic treatment (24 m vs 12 m, p = 0.007).ConclusionsOutcomes in this population were poor and declined with successive treatment. However, results suggest that further anticancer therapies in recurrent sarcoma might be beneficial.

【 授权许可】

CC BY   
© The Author(s). 2017